Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Mymetics
Mymetics
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Mymetics-led consortium awarded €8.4m to develop thermo stable and cold-chain independent vaccines
Virosome vaccine technology and HIV vaccine candidate to be used to develop scalable manufacturing process within 3.5 years
Research & Development
Mymetics to advance development of virosome-based malaria vaccine candidate
In partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the NIH
Research & Development
Mymetics’ HIV vaccine candidate to begin study at Texas Biomedical Research Institute
Follows a successfully completed smaller study at the Institute of Laboratory Animal Science (ILAS)
Research & Development
Astellas forms partnership with ClearPath to build vaccine portfolio
In-license vaccine technology for Respiratory Syncytial Virus (RSV) from Mymetics
Research & Development
Mymetics announces change of directors and management
Will explore a number of strategic opportunities for its HIV, RSV and other vaccine candidates
Pharmaceutical
Mymetics makes two appointments
New president and ceo and chairman
Subscribe now